22 May 2013
Keywords: fda, concludes, singulair, lras, associated, suicide, risk
Article | 19 January 2009
After reviewing data from clinical trials, the US Food and Drug Administration has concluded that Merck & Co's asthma drug Singulair
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
19 January 2009
21 May 2013
© 2013 thepharmaletter.com